Publication date: 9th December 2016

Conclusions

• Incorporating multilocus GRSs into CHD risk prediction improves discrimination, reclassification, and clinical decision-making. These scores provide significant incremental predictive value for CHD incidence, particularly for individuals classified as intermediate risk using traditional methods.
• CiC GRS also shows clinical utility, as the number needed to treat (NNT) to prevent 1 CHD is 36, after selectively treating with statins intermediate-risk up-classified subjects, vs. 70 if “systematic” treatment of the entire intermediate risk category.